연구동향 분석

Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson’s Disease

Hung-Li Wang Chin-Song Lu Tu-Hsueh Yeh Yu-Ming Shen Yi-Hsin Weng Ying-Zu Huang Rou-Shayn Chen Yu-Chuan Liu Yi-Chuan Cheng Hsiu-Chen Chang Ying-Ling Chen Yu-Jie Chen Yan-Wei Lin Chia Chen Hsu Huang-Li Lin Chi-Han Chiu Ching-Chi Chiu 2019년

논문상세정보
인용/피인용
' Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson’s Disease' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Rab35.
  • alpha-synuclein
  • bio-marker
  • parkinson’s disease
  • serum
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
258 0

0.0%

' Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson’s Disease' 의 참고문헌

  • α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism : a cohort study
  • Uric acid in Parkinson’s disease
  • The synaptic function of α-synuclein
    Burré J [2015]
  • The small GTPase Rab11 co-localizes with α-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity
    Chutna O [2014]
  • The many faces of α-synuclein : from structure and toxicity to therapeutic target
    Lashuel HA [2013]
  • The intellectual disability protein RAB39B selectively regulates GluA2 trafficking to determine synaptic AMPAR composition
    Mignogna ML [2015]
  • The impact of depressive symptoms in early Parkinson disease
    Ravina B [2007]
  • The emerging role of Rab GTPases in the pathogenesis of Parkinson’s disease
    Gao Y [2018]
  • The diagnosis of Parkinson’s disease
    Tolosa E [2006]
  • The Parkinson’s disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human
    Mir R [2018]
  • The G2019S variant of leucine-rich repeat kinase 2(LRRK2)alters endolysosomal trafficking by impairing the function of the GTPase RAB8A
  • Small GTPase Rab17 regulates the surface expression of kainate receptors but not α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid(AMPA)receptors in hippocampal neurons via dendritic trafficking of Syntaxin-4 protein
    Mori Y [2014]
  • Serum soluble lymphocyte activation gene-3 as a diagnostic biomarker in Parkinson’s disease : a pilot multicenter study
    Cui SS [2019]
  • Serum levels of interleukin-6 are elevated in patients with Parkinson’s disease and correlate with physical performance
    Scalzo P [2010]
  • Serum interleukin(IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism
    Brodacki B [2008]
  • Serum NFL discriminates Parkinson disease from atypical parkinsonisms
    Marques TM [2019]
  • Science, medicine, and the future : Parkinson’s disease
    Schapira AH [1999]
  • Rab29activation of the Parkinson's disease-associated LRRK2kinase
    Purlyte E [2018]
  • Rab GTPases as coordinators of vesicle traffic
    Stenmark H [2009]
  • Rab GTPases and membrane trafficking in neurodegeneration
    Kiral FR [2018]
  • Rab GTPases : the key players in the molecular pathway of Parkinson’s disease
    Shi MM [2017]
  • Quantitative analysis of synaptic vesicle Rabs uncovers distinct yet overlapping roles for Rab3a and Rab27b in Ca2+-triggered exocytosis
    Pavlos NJ [2010]
  • Prevalence of smell loss in Parkinson’s disease--a multicenter study
    Haehner A [2009]
  • Preclinical biomarkers of Parkinson disease
    Wu Y [2011]
  • Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson’s disease models
    Karpinar DP [2009]
  • Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1
    Lai YC [2015]
  • Parkinson’s disease-associated mutant LRRK2 phosphorylates Rab7L1and modifies trans-Golgi morphology
    Fujimoto T [2018]
  • Parkinson’s disease : clinical features and diagnosis
    Jankovic J [2008]
  • Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation
  • PARK14(D331Y)PLA2G6 causes early-onset degeneration of substantia nigra dopaminergic neurons by inducing mitochondrial dysfunction, ER stress, mitophagy impairment and transcriptional dysregulation in a knockin mouse model
    Chiu CC [2019]
  • Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson’s and Alzheimer’s diseases
    Williams SM [2016]
  • Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism
    Chiu CC [2015]
  • Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology
    Wilson GR [2014]
  • Local control of AMPA receptor trafficking at the postsynaptic terminal by a small GTPase of the Rab family
    Gerges NZ [2004]
  • LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson’s disease patients
    Atashrazm F [2019]
  • LRRK2 regulates synaptic vesicle endocytosis
    Shin N [2008]
  • LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation
    Bae EJ [2018]
  • Increased serum insulin-like growth factor 1 in early idiopathic Parkinson’s disease
    Godau J [2010]
  • Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson’s disease
    Chiu CC [2016]
  • Improving outcomes through early diagnosis of Parkinson’s disease
    Pagan FL [2012]
  • Epidemiology of Parkinson’s disease
    De Lau LM [2006]
  • Endosomal Rab cycles regulate Parkin-mediated mitophagy
    Yamano K [2018]
  • Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson’s Disease
    박민정 [2011]
  • Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration
    Jeong GR [2018]
  • Drug-Induced Parkinsonism
    신혜원 [2012]
  • Differentiating drug-induced parkinsonism from Parkinson’s disease : an update on non-motor symptoms and investigations
    Brigo F [2014]
  • Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles
    Yang SY [2016]
  • Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease
    El-Agnaf OM [2006]
  • CXCL12 and CXCR4 in the peripheral blood of patients with Parkinson’s disease
    Bagheri V [2018]
  • Biomarkers in Parkinson’s disease: advances and strategies
    Delenclos M [2016]
  • Biomarkers for Parkinson’s disease
    Sherer TB [2011]
  • Altered regulation of serum lysosomal acid hydrolase activities in Parkinson’s disease : a potential peripheral biomarker
    Niimi Y [2019]
  • Alpha-synuclein in Lewy bodies
  • Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice
    Dalfó E [2004]